Attorney Authored

Considerations for Innovator Drug Companies Regarding China’s Drug Patent Linkage System - 中国将施行药品专利链接制度——创新药企应如何应变

December 01, 2020

By Bruce M. Wexler,Melanie R. Rupert,Mi Zhou,Mark Sperling,

& Jake A. Silvers

This article originally appeared in IP Economy magazine.

On June 1, 2021, China will implement a drug patent linkage system that will allow drug companies to resolve patent infringement disputes before the marketing approval of competitor drugs in China.  Paul Hastings’ Global IP Co-Chair Bruce Wexler, Partner Melanie Rupert, and IP associates Mi Zhou, Mark Russell Sperling, and Jake Silvers, offer considerations for innovator drug companies in this rapidly developing area.  A reprint is available at the link below.

Click here for a PDF of the full text

Practice Areas

Intellectual Property

For More Information

Image: Melanie R. Rupert
Melanie R. Rupert

Partner, Litigation Department

Image: Bruce M. Wexler
Bruce M. Wexler

Partner, Litigation Department

Image: Mark Sperling
Mark Sperling

Associate, Litigation Department

Image: Mi Zhou
Mi Zhou

Associate, Litigation Department

Get In Touch With Us

Contact Us